sorafenib has been researched along with alvocidib in 11 studies
Studies (sorafenib) | Trials (sorafenib) | Recent Studies (post-2010) (sorafenib) | Studies (alvocidib) | Trials (alvocidib) | Recent Studies (post-2010) (alvocidib) |
---|---|---|---|---|---|
6,520 | 730 | 5,251 | 627 | 66 | 204 |
Protein | Taxonomy | sorafenib (IC50) | alvocidib (IC50) |
---|---|---|---|
Chain A, Protein (glycogen Phosphorylase) | Oryctolagus cuniculus (rabbit) | 1 | |
Glycogen synthase kinase-3 beta | Sus scrofa (pig) | 0.36 | |
[Tau protein] kinase | Sus scrofa (pig) | 0.36 | |
Cyclin-T1 | Homo sapiens (human) | 0.0243 | |
Cyclin-K | Homo sapiens (human) | 1.37 | |
Serine/threonine-protein kinase D3 | Homo sapiens (human) | 8 | |
G2/mitotic-specific cyclin-B2 | Homo sapiens (human) | 0.1571 | |
G1/S-specific cyclin-E2 | Homo sapiens (human) | 0.36 | |
Glycogen phosphorylase, muscle form | Oryctolagus cuniculus (rabbit) | 1.2 | |
Epidermal growth factor receptor | Homo sapiens (human) | 7.6 | |
Vitamin K-dependent protein C | Homo sapiens (human) | 0.1429 | |
Protein kinase C gamma type | Homo sapiens (human) | 8 | |
Protein kinase C beta type | Homo sapiens (human) | 8 | |
Tyrosine-protein kinase Lck | Homo sapiens (human) | 0.4 | |
Cyclin-dependent kinase 1 | Homo sapiens (human) | 0.1159 | |
Cyclin-dependent kinase 4 | Homo sapiens (human) | 0.1589 | |
G2/mitotic-specific cyclin-B1 | Homo sapiens (human) | 0.1464 | |
G2/mitotic-specific cyclin-B | Marthasterias glacialis (spiny starfish) | 0.2067 | |
Protein kinase C alpha type | Homo sapiens (human) | 6.2667 | |
Glycogen synthase kinase-3 beta | Rattus norvegicus (Norway rat) | 0.185 | |
Cyclin-A2 | Homo sapiens (human) | 0.3441 | |
Dual specificity protein kinase CLK1 | Mus musculus (house mouse) | 1.3 | |
G1/S-specific cyclin-D1 | Homo sapiens (human) | 0.1837 | |
Protein kinase C eta type | Homo sapiens (human) | 8 | |
G1/S-specific cyclin-E1 | Homo sapiens (human) | 0.2249 | |
Cyclin-dependent kinase 2 | Homo sapiens (human) | 0.2367 | |
G1/S-specific cyclin-D2 | Homo sapiens (human) | 0.1 | |
G1/S-specific cyclin-D3 | Homo sapiens (human) | 0.1983 | |
Vascular endothelial growth factor receptor 2 | Homo sapiens (human) | 0.4 | |
Protein kinase C iota type | Homo sapiens (human) | 8 | |
Glycogen synthase kinase-3 alpha | Homo sapiens (human) | 0.525 | |
Glycogen synthase kinase-3 beta | Homo sapiens (human) | 0.6517 | |
Cyclin-dependent kinase 7 | Homo sapiens (human) | 0.3365 | |
Cyclin-dependent kinase 9 | Homo sapiens (human) | 0.0209 | |
Cyclin-H | Homo sapiens (human) | 0.3413 | |
CDK-activating kinase assembly factor MAT1 | Homo sapiens (human) | 0.514 | |
Cyclin-A1 | Homo sapiens (human) | 0.785 | |
Cyclin-dependent kinase 6 | Homo sapiens (human) | 0.1572 | |
Cyclin-dependent-like kinase 5 | Homo sapiens (human) | 0.1747 | |
Cyclin homolog | Herpesvirus saimiri (strain 11) | 0.185 | |
Protein kinase C epsilon type | Homo sapiens (human) | 5.4933 | |
Protein kinase C theta type | Homo sapiens (human) | 8 | |
Protein kinase C zeta type | Homo sapiens (human) | 8 | |
Protein kinase C delta type | Homo sapiens (human) | 5.63 | |
Cyclin-dependent kinase 5 activator 1 | Homo sapiens (human) | 0.1765 | |
Serine/threonine-protein kinase D1 | Homo sapiens (human) | 8 | |
Dual specificity tyrosine-phosphorylation-regulated kinase 1A | Rattus norvegicus (Norway rat) | 0.3 | |
G2/mitotic-specific cyclin-B3 | Homo sapiens (human) | 0.1571 | |
Cyclin-dependent kinase 1 | Oryzias latipes (Japanese medaka) | 0.2067 | |
Cyclin-dependent kinase 12 | Homo sapiens (human) | 1.37 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 2 (18.18) | 29.6817 |
2010's | 7 (63.64) | 24.3611 |
2020's | 2 (18.18) | 2.80 |
Authors | Studies |
---|---|
Atteridge, CE; Azimioara, MD; Benedetti, MG; Biggs, WH; Carter, TA; Ciceri, P; Edeen, PT; Fabian, MA; Floyd, M; Ford, JM; Galvin, M; Gerlach, JL; Grotzfeld, RM; Herrgard, S; Insko, DE; Insko, MA; Lai, AG; Lélias, JM; Lockhart, DJ; Mehta, SA; Milanov, ZV; Patel, HK; Treiber, DK; Velasco, AM; Wodicka, LM; Zarrinkar, PP | 1 |
Atteridge, CE; Campbell, BT; Chan, KW; Ciceri, P; Davis, MI; Edeen, PT; Faraoni, R; Floyd, M; Gallant, P; Herrgard, S; Hunt, JP; Karaman, MW; Lockhart, DJ; Milanov, ZV; Morrison, MJ; Pallares, G; Patel, HK; Pritchard, S; Treiber, DK; Wodicka, LM; Zarrinkar, PP | 1 |
Russu, WA; Shallal, HM | 1 |
Ciceri, P; Davis, MI; Herrgard, S; Hocker, M; Hunt, JP; Pallares, G; Treiber, DK; Wodicka, LM; Zarrinkar, PP | 1 |
Beresini, M; Bergeron, P; Blackwood, EM; Bowman, K; Clark, K; Firestein, R; Kiefer, JR; Koehler, MF; Maskos, K; McCleland, ML; Orren, L; Ramaswamy, S; Salphati, L; Schmidt, S; Schneider, EV; Wu, J | 1 |
Aiche, S; Bassermann, F; Becker, W; Canevari, G; Casale, E; Depaolini, SR; Ehrlich, HC; Felder, ER; Feuchtinger, A; Garz, AK; Gohlke, BO; Götze, K; Greif, PA; Hahne, H; Heinzlmeir, S; Helm, D; Huenges, J; Jeremias, I; Kayser, G; Klaeger, S; Koch, H; Koenig, PA; Kramer, K; Kuster, B; Médard, G; Meng, C; Petzoldt, S; Polzer, H; Preissner, R; Qiao, H; Reinecke, M; Reiter, K; Rueckert, L; Ruland, J; Ruprecht, B; Schlegl, J; Schmidt, T; Schneider, S; Schoof, M; Spiekermann, K; Tõnisson, N; Vick, B; Vooder, T; Walch, A; Wilhelm, M; Wu, Z; Zecha, J; Zolg, DP | 1 |
Bharate, SB; Raghuvanshi, R | 1 |
Caballero, E; García-Cárceles, J; Gil, C; Martínez, A | 1 |
Greer, PA; Leduc, C; Nagaria, TS; Sangrar, W; Squire, JA; Williams, JL | 1 |
DeWille, J; Hicks, M; Hu, Q; Macrae, E | 1 |
Deng, M; Huang, F; Jia, C; Liang, H; Lin, N; Xiong, Z; Xu, J; Yao, Z | 1 |
1 review(s) available for sorafenib and alvocidib
Article | Year |
---|---|
Kinase Inhibitors as Underexplored Antiviral Agents.
Topics: Animals; Antiviral Agents; Drug Repositioning; Humans; Protein Kinase Inhibitors; Virus Diseases; Viruses | 2022 |
10 other study(ies) available for sorafenib and alvocidib
Article | Year |
---|---|
A small molecule-kinase interaction map for clinical kinase inhibitors.
Topics: Benzamides; Drug Design; Escherichia coli; Escherichia coli Proteins; Imatinib Mesylate; Microchemistry; Pharmaceutical Preparations; Piperazines; Protein Binding; Protein Interaction Mapping; Protein Kinase Inhibitors; Pyrimidines | 2005 |
A quantitative analysis of kinase inhibitor selectivity.
Topics: Binding Sites; Enzyme Activation; Humans; Phosphotransferases; Protein Binding; Protein Interaction Mapping; Protein Kinase Inhibitors; Proteome; Quantitative Structure-Activity Relationship | 2008 |
Discovery, synthesis, and investigation of the antitumor activity of novel piperazinylpyrimidine derivatives.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Discovery; Drug Screening Assays, Antitumor; Humans; Models, Molecular; Molecular Structure; Piperazines; Protein Kinase Inhibitors; Protein Kinases; Pyrimidines; Stereoisomerism; Structure-Activity Relationship | 2011 |
Comprehensive analysis of kinase inhibitor selectivity.
Topics: Catalysis; Drug Design; Enzyme Stability; High-Throughput Screening Assays; Humans; Protein Binding; Protein Kinase Inhibitors; Protein Kinases; Proteomics; Signal Transduction; Substrate Specificity | 2011 |
Design and Development of a Series of Potent and Selective Type II Inhibitors of CDK8.
Topics: | 2016 |
The target landscape of clinical kinase drugs.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cytokines; Drug Discovery; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Lung Neoplasms; Mice; Molecular Targeted Therapy; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proteomics; Xenograft Model Antitumor Assays | 2017 |
Recent Developments in the Use of Kinase Inhibitors for Management of Viral Infections.
Topics: Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Drug Approval; Drug Repositioning; High-Throughput Screening Assays; Humans; Protein Kinase Inhibitors; SARS-CoV-2; United States; United States Food and Drug Administration; Virus Diseases | 2022 |
Flavopiridol synergizes with sorafenib to induce cytotoxicity and potentiate antitumorigenic activity in EGFR/HER-2 and mutant RAS/RAF breast cancer model systems.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Cyclin-Dependent Kinases; Drug Synergism; ErbB Receptors; Female; Flavonoids; Humans; Lung Neoplasms; MCF-7 Cells; Mice; Mice, Inbred BALB C; Mice, Knockout; Mutation; Niacinamide; Phenylurea Compounds; Piperidines; raf Kinases; ras Proteins; Receptor, ErbB-2; Sorafenib; Treatment Outcome; Tumor Burden; Xenograft Model Antitumor Assays | 2013 |
JUNB promotes the survival of Flavopiridol treated human breast cancer cells.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; Female; Flavonoids; Humans; Niacinamide; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Sorafenib; Transcription Factors; Treatment Outcome | 2014 |
Inhibition of cyclin E1 sensitizes hepatocellular carcinoma cells to regorafenib by mcl-1 suppression.
Topics: Animals; Apoptosis; Bridged Bicyclo Compounds, Heterocyclic; Carcinoma, Hepatocellular; Cell Line, Tumor; Cyclic N-Oxides; Cyclin E; Drug Synergism; Flavonoids; Gene Expression Regulation, Neoplastic; Humans; Indolizines; Liver Neoplasms; Male; Mice; Myeloid Cell Leukemia Sequence 1 Protein; Oncogene Proteins; Phenylurea Compounds; Piperidines; Prognosis; Pyridines; Pyridinium Compounds; Sorafenib; STAT3 Transcription Factor; Xenograft Model Antitumor Assays | 2019 |